Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord Glioma on the basis of new 2016 world health organization classification of the central nervous system

Seong Yi, Sunkyu Choi, Dong Ah Shin, Du Su Kim, Junjeong Choi, Yoon Ha, Keung Nyun Kim, Chang Ok Suh, Jong Hee Chang, Se Hoon Kim, Do Heum Yoon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Spinal cord glioma grade IV is a rare diffuse midline glioma. H3 K27Mmutant was classified in a different entity in the 2016 World Health Organization (WHO) classification recently. No reports about prognosis of spinal cord glioma grade IV are available yet. Objective: To analyze the prognostic factors for spinal cord glioma grade IV. Methods: Twenty-five patients with spinal cord glioma of grade IV who underwent surgery in a single institute were selected. All grade IV spinal cord glioma histologically confirmed as glioblastoma or "diffuse midline glioma with H3 K27M-mutant" by the 2016 WHO classification of the central nervous system were included. Basic demographics, treatment modalities, and pathological tumor molecular profiles were investigated for prognosis. Results: Mean age was 39.1 yr; male to female ratio was 18 : 7. Tumor was located in thoracic cord (53.3%), cervical cord (40%), and lumbar area (6.7%). Median overall survival was 37.1 mo; median disease-free survival was 18.5 mo. Treatment modality showed no statistical difference. Only K27M profile showed significant prognostic value, 20 patients (80%) showed K27M mutation positive, K27M mutation patients showed longer overall survival (40.07 mo) than K27M negative patients (11.63 mo, P < .0001), and disease-free survival (20.85 vs 8.72 mo, P= .0241). Conclusion: This study is the first and largest report of the prognosis of primary spinal cord grade IV glioma using the new WHO classification. This study reported survival analysis and prognostic factors, and revealed that H3.3 K27M mutation is not a major poor prognostic factor. Further studies to explore K27M mutations needed for risk stratification and therapy optimization.

Original languageEnglish
Pages (from-to)1072-1081
Number of pages10
JournalNeurosurgery
Volume84
Issue number5
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Glioma
Spinal Cord
Central Nervous System
Mutation
Survival
Disease-Free Survival
Glioblastoma
Survival Analysis
Neoplasms
Therapeutics
Demography

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

@article{8331ba99991e4aa5afe9fe841de8440a,
title = "Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord Glioma on the basis of new 2016 world health organization classification of the central nervous system",
abstract = "Background: Spinal cord glioma grade IV is a rare diffuse midline glioma. H3 K27Mmutant was classified in a different entity in the 2016 World Health Organization (WHO) classification recently. No reports about prognosis of spinal cord glioma grade IV are available yet. Objective: To analyze the prognostic factors for spinal cord glioma grade IV. Methods: Twenty-five patients with spinal cord glioma of grade IV who underwent surgery in a single institute were selected. All grade IV spinal cord glioma histologically confirmed as glioblastoma or {"}diffuse midline glioma with H3 K27M-mutant{"} by the 2016 WHO classification of the central nervous system were included. Basic demographics, treatment modalities, and pathological tumor molecular profiles were investigated for prognosis. Results: Mean age was 39.1 yr; male to female ratio was 18 : 7. Tumor was located in thoracic cord (53.3{\%}), cervical cord (40{\%}), and lumbar area (6.7{\%}). Median overall survival was 37.1 mo; median disease-free survival was 18.5 mo. Treatment modality showed no statistical difference. Only K27M profile showed significant prognostic value, 20 patients (80{\%}) showed K27M mutation positive, K27M mutation patients showed longer overall survival (40.07 mo) than K27M negative patients (11.63 mo, P < .0001), and disease-free survival (20.85 vs 8.72 mo, P= .0241). Conclusion: This study is the first and largest report of the prognosis of primary spinal cord grade IV glioma using the new WHO classification. This study reported survival analysis and prognostic factors, and revealed that H3.3 K27M mutation is not a major poor prognostic factor. Further studies to explore K27M mutations needed for risk stratification and therapy optimization.",
author = "Seong Yi and Sunkyu Choi and {Ah Shin}, Dong and {Su Kim}, Du and Junjeong Choi and Yoon Ha and Kim, {Keung Nyun} and Suh, {Chang Ok} and Chang, {Jong Hee} and Kim, {Se Hoon} and Yoon, {Do Heum}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/neuros/nyy150",
language = "English",
volume = "84",
pages = "1072--1081",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord Glioma on the basis of new 2016 world health organization classification of the central nervous system. / Yi, Seong; Choi, Sunkyu; Ah Shin, Dong; Su Kim, Du; Choi, Junjeong; Ha, Yoon; Kim, Keung Nyun; Suh, Chang Ok; Chang, Jong Hee; Kim, Se Hoon; Yoon, Do Heum.

In: Neurosurgery, Vol. 84, No. 5, 01.01.2019, p. 1072-1081.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord Glioma on the basis of new 2016 world health organization classification of the central nervous system

AU - Yi, Seong

AU - Choi, Sunkyu

AU - Ah Shin, Dong

AU - Su Kim, Du

AU - Choi, Junjeong

AU - Ha, Yoon

AU - Kim, Keung Nyun

AU - Suh, Chang Ok

AU - Chang, Jong Hee

AU - Kim, Se Hoon

AU - Yoon, Do Heum

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Spinal cord glioma grade IV is a rare diffuse midline glioma. H3 K27Mmutant was classified in a different entity in the 2016 World Health Organization (WHO) classification recently. No reports about prognosis of spinal cord glioma grade IV are available yet. Objective: To analyze the prognostic factors for spinal cord glioma grade IV. Methods: Twenty-five patients with spinal cord glioma of grade IV who underwent surgery in a single institute were selected. All grade IV spinal cord glioma histologically confirmed as glioblastoma or "diffuse midline glioma with H3 K27M-mutant" by the 2016 WHO classification of the central nervous system were included. Basic demographics, treatment modalities, and pathological tumor molecular profiles were investigated for prognosis. Results: Mean age was 39.1 yr; male to female ratio was 18 : 7. Tumor was located in thoracic cord (53.3%), cervical cord (40%), and lumbar area (6.7%). Median overall survival was 37.1 mo; median disease-free survival was 18.5 mo. Treatment modality showed no statistical difference. Only K27M profile showed significant prognostic value, 20 patients (80%) showed K27M mutation positive, K27M mutation patients showed longer overall survival (40.07 mo) than K27M negative patients (11.63 mo, P < .0001), and disease-free survival (20.85 vs 8.72 mo, P= .0241). Conclusion: This study is the first and largest report of the prognosis of primary spinal cord grade IV glioma using the new WHO classification. This study reported survival analysis and prognostic factors, and revealed that H3.3 K27M mutation is not a major poor prognostic factor. Further studies to explore K27M mutations needed for risk stratification and therapy optimization.

AB - Background: Spinal cord glioma grade IV is a rare diffuse midline glioma. H3 K27Mmutant was classified in a different entity in the 2016 World Health Organization (WHO) classification recently. No reports about prognosis of spinal cord glioma grade IV are available yet. Objective: To analyze the prognostic factors for spinal cord glioma grade IV. Methods: Twenty-five patients with spinal cord glioma of grade IV who underwent surgery in a single institute were selected. All grade IV spinal cord glioma histologically confirmed as glioblastoma or "diffuse midline glioma with H3 K27M-mutant" by the 2016 WHO classification of the central nervous system were included. Basic demographics, treatment modalities, and pathological tumor molecular profiles were investigated for prognosis. Results: Mean age was 39.1 yr; male to female ratio was 18 : 7. Tumor was located in thoracic cord (53.3%), cervical cord (40%), and lumbar area (6.7%). Median overall survival was 37.1 mo; median disease-free survival was 18.5 mo. Treatment modality showed no statistical difference. Only K27M profile showed significant prognostic value, 20 patients (80%) showed K27M mutation positive, K27M mutation patients showed longer overall survival (40.07 mo) than K27M negative patients (11.63 mo, P < .0001), and disease-free survival (20.85 vs 8.72 mo, P= .0241). Conclusion: This study is the first and largest report of the prognosis of primary spinal cord grade IV glioma using the new WHO classification. This study reported survival analysis and prognostic factors, and revealed that H3.3 K27M mutation is not a major poor prognostic factor. Further studies to explore K27M mutations needed for risk stratification and therapy optimization.

UR - http://www.scopus.com/inward/record.url?scp=85060915886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060915886&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyy150

DO - 10.1093/neuros/nyy150

M3 - Article

C2 - 29718432

AN - SCOPUS:85060915886

VL - 84

SP - 1072

EP - 1081

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -